DURABLE-I ground-breaking clinical study results presented at the 2017 AF Symposium

Orlando, January 31 2017

Results from EPD’s DURABLE-I clinical trial, whose principal investigator is Professor Evgeny A Pokushalov, were presented for the first time at the 2017 AF Symposium by Professor Karl-Heinz Kuck, Head of the Department of Cardiology at the Asklepios Klinik in Hamburg, Germany. The presentation, “DURABLE-I Study: Real-time gap detection during AF ablation using dielectric sensing”, […]

Read Story

EPD Meets Another Significant Milestone, Completing Its First Human Experience

Tortola, April 28 2016 – EPD has completed its first human procedure, having successfully tested its revolutionary D700 Dielectric Sensing System at the Meshalkin State Research Institute of Circulation Pathology in Novosibirsk, Russia, headed by Professor Evgeny Pokushalov. The EPD D700 System employs dielectric sensing for guided personalized intra-cardiac navigation, and provides electrode-tissue contact quality, […]

Read Story

Efficiency and Efficacy Key to Driving AF Ablation Growth

London, March 7 2016

Prof. Shlomo Ben-Haim, Founder of Hobart Group, authored “How Innovation Can Unleash Tremendous Growth in the $3.4 Billion AF Ablation Market”, published…

Read Story

EPD’s real-time tissue characterization technology to be presented at the IDSS

Tortola, February 29 2016

EPD will present its novel real-time D700 tissue characterization technology for permanent transmural ablation at the upcoming 13th International Dead Sea Symposium (IDSS)…

Read Story

The Final Chapter in AF Ablation: In-Vivo Tissue Characterization

Ghent, 4 June, 2015

An editorial written by Mattias Duytschaever, Philippe Taghji and Rene Tavernier referring to the seminal paper ‘EFFICAS II: optimization of catheter…

Read Story

D700 technology presented in a private setting at the HRS

Boston, 13 May, 2015

EPD presented its proprietary catheter-based cardiac ablation platform in a private setting at the annual Heart Rhythm Society (HRS) conference in Boston…

Read Story

EP Dynamics secures funding

22 January, 2015

EP Dynamics (EPD) has been successful in securing further funding to commercialize its technology…

Read Story

The role of dormant PV conduction in AF recurrence

San Francisco, 8 May, 2014

Results from the Adenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination (ADVICE) trial were presented…

Read Story

EP Dynamics receives seed funding

1 May, 2014

With the goal of commercializing and bringing to the market a novel solution which would make catheter-based cardiac ablation procedures more efficient and effective…

Read Story

About atrial fibrillation

Atrial fibrillation (AF) is an abnormal heart rhythm which is characterized by irregular and rapid beating.  As the most common arrhythmia, it affects about 3% of the population in North America and Europe and is the second leading cause of stroke.

About EP Dynamics

EP Dynamics (EPD), a member of the Hobart Group companies, is dedicated to improving the efficacy and efficiency of minimally invasive catheter-based procedures performed to treat cardiac arrhythmias.  EPD is developing a proprietary dielectric-based platform that enables the measurement of the permanency, transmurality and continuity of cardiac AF ablation lesions, thereby significantly improving the efficacy of AF ablation.  The platform also provides an estimated ablation depth, reports catheter contact quality and gives an accurate 3D localization of EP catheters.  For more information, please visit

About Hobart Group

The Hobart Group develops and commercializes medical technologies which target top healthcare markets with significant unmet needs.  Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation.  Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the USA and Asia.  For more information, visit

Media kit

Reporters are welcome to use the following materials related to EPD and its products